Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alx Oncology Holdings (ALXO) Other Non-Current Assets (2019 - 2026)

Alx Oncology Holdings' Other Non-Current Assets history spans 5 years, with the latest figure at $14.9 million for Q4 2023.

  • On a quarterly basis, Other Non-Current Assets changed 0.25% to $14.9 million in Q4 2023 year-over-year; TTM through Dec 2023 was $14.9 million, a 0.25% change, with the full-year FY2023 number at $14.9 million, changed 0.25% from a year prior.
  • Other Non-Current Assets hit $14.9 million in Q4 2023 for Alx Oncology Holdings, up from $11.0 million in the prior quarter.
  • Over the last five years, Other Non-Current Assets for ALXO hit a ceiling of $15.7 million in Q1 2022 and a floor of $7000.0 in Q4 2019.
  • Historically, Other Non-Current Assets has averaged $5.9 million across 5 years, with a median of $641000.0 in 2020.
  • The widest YoY moves for Other Non-Current Assets: up 16542.42% in 2023, down 99.58% in 2023.
  • Tracing ALXO's Other Non-Current Assets over 5 years: stood at $7000.0 in 2019, then soared by 42.86% to $10000.0 in 2020, then skyrocketed by 1340.0% to $144000.0 in 2021, then skyrocketed by 10269.44% to $14.9 million in 2022, then dropped by 0.25% to $14.9 million in 2023.
  • Business Quant data shows Other Non-Current Assets for ALXO at $14.9 million in Q4 2023, $11.0 million in Q3 2023, and $10.9 million in Q2 2023.